for most of us (2/3?) Abilify builds up (pharmarkokinetic?) tolerance.
Any theories why?
Maybe workarounds possible?
It would be interesting to see if the Abilify loss of effect reverses itself after discontinuing the drug for some weeks, or whether the loss of effect is permanent.
In ME/CFS it is sometimes reported that drugs which have helped stop working after some time (like after a few weeks or months), and that even if you take a break from these drugs, they still will not work again when you restart, because the tolerance somehow becomes permanent.
I had this permanent tolerance appear when I tried one of Dr Jay Goldstein's ME/CFS drugs: Wellbutrin (bupropion), an antidepressant with stimulant properties. For the first two weeks on low-dose Wellbutrin, I found my brain fog was not only banished, but I my concentration was even better than when I was healthy. And my mood and mental energy were also riding high. I thought I'd found my personal escape from ME/CFS.
Then exactly two weeks after starting this drug, it's benefits just vanished, even though I made no changes to any of my regimen. I was never able to get Wellbutrin to work again, even after a two month break from it.
I really wanted to get to the bottom of this mystery, as Wellbutrin worked so well for me, but was unable to. I looked at things like down-regulation of G protein receptor tolerance (see
this post), which Dr Goldstein thought might explain the loss of effect phenomenon in ME/CFS, and tried some of Goldstein's suggestions to prevent the tolerance, but to no avail.
In any case, I don't think permanent loss of effect can be due to ordinary day-to-day receptor down-regulation and up-regulation, because such mechanisms are dynamic, and for short-term use of drugs, receptor populations normally rebound once the drug is stopped.
We need to consider mechanisms which once set become permanent, to reflect the permanent loss of effect experienced. So one obvious area might be epigenetic mechanisms, as these are long-lasting.
What epigenetic mechanisms might be at play in permanent down-regulation of receptors?
Well in the down-regulation of GABA receptors caused by benzodiazepine use, it appears to be
histone deacetylation (an epigenetic mechanism) which is responsible. See
this study.
If the loss of effect of Abilify also involves histone deacetylation, then possibly
histone deacetylase (HDAC)
inhibitors might act to restore the effect of Abilify. HDAC inhibitors
have been shown to reduce morphine tolerance.
Valproic acid is one HDAC inhibitor, and there are several other HDAC inhibitor drugs available.
Butyrate is another HDAC inhibitor. The probiotic Clostridium butyricum is a butyrate-producing bacterium.
An interesting article on preventing drug tolerance is
here.